Clinical Trials Directory

Trials / Unknown

UnknownNCT05889767

Exercise-Induced Gut Permeability in Normal-weight Obesity

Indicators of Gut Permeability in Normal-weight Obesity in Response to Brief, Maximal and Sustained, Submaximal Exercise

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Oklahoma State University · Academic / Other
Sex
All
Age
18 Years – 50 Years
Healthy volunteers
Accepted

Summary

Exercise acutely increases gut permeability and inflammation, even in healthy populations. However, whether this response differs in groups at-risk for CVD that present with low-grade inflammation (e.g., normal-weight obesity) has yet to be examined. The investigators aim to measure serum indicators of gut permeability in those with normal-weight obesity pre- and post-short, intense exercise and sustained, moderate exercise

Detailed description

The investigator's overall goal is to examine how indicators of gut permeability change in response to exercise in individuals with normal-weight obesity (i.e., normal body mass index \[BMI\] and high body fat percent) relative to those with a normal BMI and low body fat percent and those with a BMI in the obesity range and high body fat percent. The investigators will examine indicators of gut permeability (specified in primary outcomes) in response to a short, intense bout of exercise (i.e., VO2 max test on a cycle ergometer) and sustained, moderate bout of exercise (i.e., 45 minutes at 65% measured VO2 max on a cycle ergometer). Additionally, the investigators will measure basic anthropometrics, blood lipids and glucose, and body composition with DXA.

Conditions

Interventions

TypeNameDescription
OTHERExercise tests (VO2 max test and 45-minute exercise session at 65% VO2 max)All participants will complete two exercise sessions: 1. VO2 max test on a cycle ergometer 2. Moderate exercise session (45 minutes at 65% measured VO2 max)

Timeline

Start date
2023-01-10
Primary completion
2023-08-01
Completion
2023-08-01
First posted
2023-06-05
Last updated
2023-06-05

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05889767. Inclusion in this directory is not an endorsement.